Fate Therapeutics (NASDAQ:FATE) “Buy” Rating Reaffirmed Today By Piper Jaffray; The TP is $20.0000

May 17, 2018 - By Robert Sims

Investors sentiment decreased to 1.58 in Q4 2017. Its down 0.21, from 1.79 in 2017Q3. It worsened, as 9 investors sold Fate Therapeutics, Inc. shares while 17 reduced holdings. 17 funds opened positions while 24 raised stakes. 32.27 million shares or 31.43% more from 24.55 million shares in 2017Q3 were reported.

Tiaa Cref Mgmt Limited Co has 0% invested in Fate Therapeutics, Inc. (NASDAQ:FATE) for 96,262 shares. Balyasny Asset Ltd Liability stated it has 0% of its portfolio in Fate Therapeutics, Inc. (NASDAQ:FATE). Franklin Resource accumulated 6.04 million shares or 0.02% of the stock. 33,440 were accumulated by Rhumbline Advisers. New York State Common Retirement Fund invested 0% of its portfolio in Fate Therapeutics, Inc. (NASDAQ:FATE). Doheny Asset Mngmt Ca has invested 0.04% of its portfolio in Fate Therapeutics, Inc. (NASDAQ:FATE). Redmile Group Limited Liability invested 1.46% in Fate Therapeutics, Inc. (NASDAQ:FATE). Deutsche Financial Bank Ag owns 0% invested in Fate Therapeutics, Inc. (NASDAQ:FATE) for 86,531 shares. Susquehanna Intl Gp Llp has invested 0% in Fate Therapeutics, Inc. (NASDAQ:FATE). Price T Rowe Associate Md has invested 0% of its portfolio in Fate Therapeutics, Inc. (NASDAQ:FATE). Moreover, Dimensional Fund Advsr L P has 0% invested in Fate Therapeutics, Inc. (NASDAQ:FATE) for 23,500 shares. Jpmorgan Chase & owns 0% invested in Fate Therapeutics, Inc. (NASDAQ:FATE) for 29,048 shares. Massachusetts-based Polaris Venture Mngmt V Limited Co has invested 12.77% in Fate Therapeutics, Inc. (NASDAQ:FATE). Moreover, Comml Bank Of Montreal Can has 0% invested in Fate Therapeutics, Inc. (NASDAQ:FATE) for 3,000 shares. Vigilant Mngmt Lc has 1,000 shares for 0% of their portfolio.

Fate Therapeutics (NASDAQ:FATE) Rating Reaffirmed

Recently, In a research report revealed to investors on Wednesday, 16 May, Fate Therapeutics (NASDAQ:FATE) shares have had their “Buy” Rating restate by stock analysts at Piper Jaffray, who currently has a $20.0000 target price per share on company. This target by Piper Jaffray suggests the possibile upside of 91.57 % from the last stock close.

Fate Therapeutics, Inc. (NASDAQ:FATE) Ratings Coverage

Among 7 analysts covering Fate Therapeutics (NASDAQ:FATE), 5 have Buy rating, 0 Sell and 2 Hold. Therefore 71% are positive. Fate Therapeutics has $20 highest and $7.0 lowest target. $16.50’s average target is 58.05% above currents $10.44 stock price. Fate Therapeutics had 12 analyst reports since December 12, 2017 according to SRatingsIntel. The rating was maintained by Wedbush on Tuesday, March 6 with “Outperform”. BMO Capital Markets maintained the shares of FATE in report on Tuesday, March 6 with “Outperform” rating. The firm earned “Buy” rating on Friday, April 6 by Wells Fargo. H.C. Wainwright maintained it with “Hold” rating and $1200 target in Thursday, March 29 report. The rating was downgraded by Raymond James on Tuesday, March 6 to “Hold”. H.C. Wainwright maintained Fate Therapeutics, Inc. (NASDAQ:FATE) rating on Tuesday, March 20. H.C. Wainwright has “Hold” rating and $12.0 target. The firm has “Neutral” rating by H.C. Wainwright given on Tuesday, March 6. The company was maintained on Thursday, March 15 by Piper Jaffray. On Wednesday, December 13 the stock rating was maintained by H.C. Wainwright with “Buy”. Piper Jaffray maintained Fate Therapeutics, Inc. (NASDAQ:FATE) rating on Tuesday, March 6. Piper Jaffray has “Buy” rating and $20.0 target.

The stock increased 2.55% or $0.26 during the last trading session, reaching $10.44. About 341,324 shares traded. Fate Therapeutics, Inc. (NASDAQ:FATE) has risen 112.01% since May 18, 2017 and is uptrending. It has outperformed by 100.46% the S&P500.

Analysts await Fate Therapeutics, Inc. (NASDAQ:FATE) to report earnings on August, 13. They expect $-0.24 EPS, down 4.35 % or $0.01 from last year’s $-0.23 per share. After $-0.27 actual EPS reported by Fate Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -11.11 % EPS growth.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company has market cap of $551.84 million. The Company’s immuno-oncology product candidates include FATE-NK100, a natural killer cell cancer immunotherapy that consists of adaptive memory NK cells; engineered hnCD16 induced pluripotent stem cells (iPSC)-derived natural killer cell therapy candidates for hematologic/solid tumors; and engineered chimeric antigen receptor iPSC-derived T cell therapy product candidates for hematologic/solid tumors. It currently has negative earnings. The companyÂ’s immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; and ToleraCyte for the treatment of autoimmune and inflammatory diseases; engineered iPSC-derived CD34+ cell therapy for immune disorders.

More notable recent Fate Therapeutics, Inc. (NASDAQ:FATE) news were published by: Benzinga.com which released: “Benzinga’s Daily Biotech Pulse: FDA Panel Nod For Akcea, Synergy’s Revenue Miss, FDA Warns E-Liquid Makers Again” on May 11, 2018, also Nasdaq.com with their article: “Fate Therapeutics Reports First Quarter 2018 Financial Results and Highlights Operational Progress” published on May 10, 2018, Nasdaq.com published: “Fate Therapeutics and Memorial Sloan Kettering Cancer Center Expand Scope of License Agreement to include Gene …” on May 16, 2018. More interesting news about Fate Therapeutics, Inc. (NASDAQ:FATE) were released by: Benzinga.com and their article: “50 Biggest Movers From Friday” published on May 14, 2018 as well as Seekingalpha.com‘s news article titled: “Fate Therapeutics’ (FATE) CEO Scott Wolchko on Q1 2018 Results – Earnings Call Transcript” with publication date: May 11, 2018.

Fate Therapeutics, Inc. (NASDAQ:FATE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.